Previous 10 | Next 10 |
Akebia Therapeutics ( NASDAQ: AKBA ) added ~11% pre-market Friday after announcing that an independent group of medical experts has recommended the approval of its lead asset, vadadustat, as a treatment for anemia linked to chronic kidney disease in adults on dialysis. With the so...
Akebia Receives Positive CHMP Opinion in Europe for Vafseo™ (vadadustat) for the Treatment of Symptomatic Anaemia Associated with Chronic Kidney Disease in Adults on Chronic Maintenance Dialysis PR Newswire CAMBRIDGE, Mass. , Feb. 23, 2023 /PRNewswire/ -- ...
Kidney-disease drug developer Akebia Therapeutics ( NASDAQ: AKBA ) lost ~9% pre-market Tuesday after announcing that the FDA issued a second interim response in its appeal for lead candidate vadadustat developed as a therapy for anemia due to chronic kidney disease. In early 2022,...
Akebia Therapeutics Received Interim Response from the FDA to Appeal for Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease PR Newswire CAMBRIDGE, Mass. , Feb. 21, 2023 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: A...
Kidney-disease drug developer Akebia Therapeutics ( NASDAQ: AKBA ) added ~28% in the morning hours Thursday after GSK ( GSK ) announced that the FDA approved its anemia treatment Jesduvroq for adults on dialysis due to chronic kidney disease (CKD). An oral hypoxia-inducibl...
Summary Travere Therapeutics, Inc. is set to find out on Feb 17th whether the FDA has granted accelerated approval to lead drug candidate Sparsentan. Indicated for kidney disease IgAN and FSGS, the accelerated approval would be granted based on the drug's ability to reduce proteinuria. ...
The new year is rapidly approaching, which means figuring out how to make money in the stock market. One of the asset classes that has continued outperforming broader markets daily has been stocks under $5. Known as penny stocks , these cheap shares are well-known for their short-term yet...
Kidney disease drug developer Akebia Therapeutics ( NASDAQ: AKBA ) announced Wednesday that its subsidiary Keryx Biopharmaceuticals inked an agreement to grant an exclusive license to Averoa SAS to develop and sell ferric citrate in certain European markets and Turkey. Per the terms, ...
Akebia Therapeutics ( NASDAQ: AKBA ) on Thursday said it had got a response from the U.S. Food and Drug Administration (FDA) to its appeal to the regulator's rejection of its treatment for anemia due to kidney disease. The micro-cap biopharma's shares hit a historic low earlier th...
Akebia Therapeutics Received Interim Response to Appeal for Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease from the FDA PR Newswire CAMBRIDGE, Mass. , Dec. 22, 2022 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: A...
News, Short Squeeze, Breakout and More Instantly...
Akebia Therapeutics Inc. Company Name:
AKBA Stock Symbol:
NASDAQ Market:
Akebia Therapeutics Inc. Website:
Akebia Therapeutics Provides Update on Continued Momentum of Commercial Launch of Vafseo® (vadadustat) Tablets PR Newswire Akebia regains full rights to sell Vafseo® (vadadustat) Tablets in the U.S. following the execution of a royalty-based termination agreement wit...
Akebia Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference PR Newswire CAMBRIDGE, Mass. , June 27, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purp...
Akebia Therapeutics Appoints Erik Ostrowski as Chief Financial Officer and Chief Business Officer PR Newswire CAMBRIDGE, Mass. , June 24, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with t...